Subjective and physiological effects after controlled Sativex and oral THC administration.
about
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewTriphasic blood pressure responses to cannabinoids: do we understand the mechanism?Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendationsCan reduce--the effects of chat-counseling and web-based self-help, web-based self-help alone and a waiting list control program on cannabis use in problematic cannabis users: a randomized controlled trial.A Web-Based Self-Help Intervention With and Without Chat Counseling to Reduce Cannabis Use in Problematic Cannabis Users: Three-Arm Randomized Controlled Trial.Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images.Variable activation in striatal subregions across components of a social influence task in young adult cannabis usersCannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine.Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.Controlled-deactivation cannabinergic ligands.Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users.Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review.Cannabinoid signaling in health and disease.Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.The Use of Cannabis for Headache Disorders.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.Cardiovascular Complications of Marijuana and Related Substances: A Review.Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.
P2860
Q21129107-C19DE81E-7547-4F30-83B4-15F33211E6ADQ27005619-1ADF2E65-B788-41AA-9FE4-73AA2A660A49Q27025612-F86132C5-127B-4C4C-A86E-EB685BC0607DQ34192001-08886074-13F5-48AD-A9EB-C2065ED5AAFBQ34306281-645D84A8-B43F-4B7E-BCB6-49E0739DA5DDQ34453438-EAC035C1-508A-4C7A-A61B-7C80E67A482FQ35042428-51C48522-439D-463A-9507-910B2613BFC4Q36273092-ECB75175-2F11-43AF-A86C-B0D920C4A91BQ36677757-D533DB4B-5564-48CB-B944-DD5F0633A2D2Q36876852-1C727EDC-7EE2-4754-B1B0-E078CC1872F2Q36918789-48FA8257-2993-4A13-81F6-973C97684701Q36953261-FECE72A4-4A26-4D8B-ADF4-4C29F681D07CQ36987924-FB791282-6409-4390-BCB8-3E36E2B1ACFDQ37006281-538238A1-496F-4A8B-8D59-96B080AF99D9Q37527191-F0D3970C-36FD-4A1A-A014-F38ADAE83BB4Q37671286-80EC3358-D583-42BC-9D9E-BB7033A04B6AQ37705501-5E8DE592-B7C0-439A-BE09-EDD3A16FB94EQ38041231-1AFBA8DC-7F95-4347-8CB4-F3FE94BD7898Q38102053-FA037810-E290-4847-BEAD-4506FCF7A6F4Q38199658-07F438B0-9A40-4F5B-B7D3-1F5954834F76Q38212376-2C3B31CB-F471-4DCF-8B56-C1F8CE6EB8FDQ38825532-54CA0032-6059-473A-B76F-CFDED6D364FBQ39163671-7A15A3F8-05C8-481C-B91C-82E1E7EEF3DEQ39178828-01252854-A5A3-4D35-BEEE-4E8E52DA60BEQ40719201-3A111C6D-D0B8-4BBA-8226-0BFCD2FFB954Q42258328-E48424CC-8584-44DE-954F-281DABCF7D6BQ45288843-4EE3B37D-E217-4D15-8323-51FBCA6E5A60Q47316420-5CE26C22-3D27-4489-9AC7-63CDC5BAD9E5Q47550362-41DCB8B3-AEEB-45FD-AD23-37D1D5032573Q47963305-FB24AF44-EB3C-4DD5-A2F6-F5082FC86442
P2860
Subjective and physiological effects after controlled Sativex and oral THC administration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Subjective and physiological e ...... x and oral THC administration.
@en
Subjective and physiological e ...... x and oral THC administration.
@nl
type
label
Subjective and physiological e ...... x and oral THC administration.
@en
Subjective and physiological e ...... x and oral THC administration.
@nl
prefLabel
Subjective and physiological e ...... x and oral THC administration.
@en
Subjective and physiological e ...... x and oral THC administration.
@nl
P2093
P2860
P356
P1476
Subjective and physiological e ...... x and oral THC administration.
@en
P2093
E L Karschner
M A Huestis
R P McMahon
R S Goodwin
W D Darwin
P2860
P304
P356
10.1038/CLPT.2010.318
P407
P577
2011-02-02T00:00:00Z